19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder

American Journal of Psychiatry

Volumn 154, Issue 4, 1997, Pages 516-522

  Strauss, Wayne L ^a   Layton, Matthew E ^a   Hayes, Cecil E ^a   Dager, Stephen R ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; DIAGNOSTIC AGENT; FLUORINE; FLUOXETINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBSESSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; ADOLESCENT; AGED; BLOOD; BRAIN; BRAIN LEVEL; DRUG ADMINISTRATION; DRUG EFFECT; METABOLISM; MIDDLE AGED; OBSESSIVE COMPULSIVE DISORDER; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; BRAIN; BRAIN CHEMISTRY; DRUG ADMINISTRATION SCHEDULE; FLUORINE; FLUOXETINE; FLUVOXAMINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 0030610929     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.154.4.516     Document Type: Article

References (33)

1. Dager SR, Steen RG: Applications of magnetic resonance spectroscopy to the investigation of neuropsychiatric disorders. Neuropsychopharmacology 1992; 6:249-266
2. 19F nuclear magnetic resonance spectroscopy: a potential monitor of 5-fluorouracil pharmacokinetics and metabolism. Invest New Drugs 1989; 7:5-12
3. 19F nuclear magnetic resonance imaging of drug distribution in vivo: the disposition of an antifolate anticancer drug in mice. Magn Reson Med 1991; 17:189-196
4. 19F nuclear magnetic resonance spectroscopy of neuroleptics: the first in vivo pharmacokinetics of trifluoperazine in the rat brain and the first in vivo spectrum of fluphenazine in the human brain. Biol Psychiatry 1991; 30:656-662
5. 19F-nuclear magnetic resonance spectroscopy study. Psychiatry Res 1992; 45:95-104
6. 19F MR spectroscopy. J Neural Transm Gen Sect 1995; 99:1-6
7. 19F spin relaxation and localized spectroscopy of fluoxetine in human brain. Magn Reson Med 1994; 31:204-211
8. Renshaw PF, Guimaraes AR, Fava M, Rosenbaum JF, Pearlman JD, Flood JG, Puopolo PR, Clancy K, Gonzalez RG: Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. Am J Psychiatry 1992; 149:1592-1594
9. Karson CN, Newton JE, Livingston R, Jolly JB, Cooper TB, Sprigg J, Komoroski RA: Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci 1993; 5:322-329
10. Miner CM, Davidson JR, Potts NL, Tupler LA, Charles HC, Krishnan KR: Brain fluoxetine measurements using fluorine magnetic resonance spectroscopy in patients with social phobia. Biol Psychiatry 1995; 38:696-698
11. Jenike MA, Hyman S, Baer L, Holland A, Minichiello WE, Buttolph L, Summergrad P, Seymour R, Ricciardi J: A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am J Psychiatry 1990; 147: 1209-1215
12. Freeman CP, Trimble MR, Deakin JF, Stokes TM, Ashford JJ: Fluvoxamine versus clomipramine in the treatment of obsessive-compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 1994; 55:301-305
13. den Boer JA, Westenberg HG, Kamerbeek WD, Verhoeven WM, Kahn RS: Effect of serotonin uptake inhibitors in anxiety disorders: a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 1987; 2:21-32
14. March JS, Kobak KA, Jefferson JW, Mazza J, Greist JH: A double-blind, piacebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression. J Clin Psychiatry 1990; 51:200-202
15. van Vliet IM, den Boer JA, Westenberg HG: Psychopharmacological treatment of social phobia: a double-blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl) 1994; 115:128-134
16. de Bree H, Van der Schoot Post L: Fluvoxamine maleate: disposition in man. Eur J Drug Metab Pharmacokinet 1983; 8:175-179
17. de Vries MH, Raghoebar M, Mathlener IS, van Harten J: Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monit 1992; 14:493-498
18. De Vries MH, Van Harten J, Van Bemmel P, Raghoebar M: Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects. Biopharm Drug Dispos 1993; 14: 291-296
19. Wilde MI, Plosker GL, Benfield P: Fluvoxamine: an updated review of its pharmacology, and therapeutic use in depressive illness. Drugs 1993; 46:895-924
20. van Harten J: Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1995; 29(suppl 1):1-9
21. Overmars H, Scherpenisse PM, Post LC: Fluvoxamine maleate: metabolism in man. Eur J Drug Metab Pharmacokinet 1983; 8: 269-280
22. Insel TR, Murphy DL, Cohen RM, Alterman I, Kilts C, Linnoila M: Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983; 40:605-612
23. Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS: Efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with placebo. Arch Gen Psychiatry 1989; 46:36-44
24. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS: The Yale-Brown Obsessive Compulsive Scale, II: validity. Arch Gen Psychiatry 1989; 46:1012-1016
25. Foglia JP, Birder LA, Perel JM: Determination of fluvoxamine in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1989; 495:295-302
26. Hayes CE: An efficient, highly homogenous radiofrequency coil for whole-body NMR images at 1.5 T. J Magn Reson 1985; 63: 622-628
27. Hayes CE: An adjustable RF coil loading device. Magn Reson Imaging 1993; 11:81-86
28. Bolo NR, Hode Y, Macher JP: Comparison of plasma and in vivo brain levels of fluvoxamine measured by fluorine NMR spectroscopy during drug washout (abstract). Proc Soc Magn Reson Med 1996; 2:1179
29. Palmer K, Benfield P: Fluvoxamine: an overview of its pharmacological properties and review of its therapeutic potential in nondepressive disorders. CNS Drugs 1994; 1:57-87
30. Dager S, Yim J, Khalil G, Artru A, Bowden D, Kenny M: Application of a novel fiber-optic biosensor in situ to investigate the metabolic effect of lactate infusion. Neuropsychopharmacology 1995; 12:307-313
31. Schmalzing G: The role of a transmembrane pH gradient in uptake and release of imipramine and haloperidol in synaptosomes. Mol Pharmacol 1988; 34:888-895
32. Koran LM, Cain JW, Dominguez RA, Rush AJ, Thiemann S: Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? Am J Psychiatry 1996; 153:1450-1454
33. Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL: A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980; 17:102-105